In patients with PIK3CA-mutant, HR+/HER2– advanced breast cancer, the addition of inavolisib to palbociclib and fulvestrant substantially extended PFS to 17.2 months compared to 7.3 months with placebo. This evidence concerns the gene PIK3CA and breast carcinoma.